Phase I/II trial of dose reduced capecitabine in elderly or frail patients with untreated advanced colorectal cancer.

被引：0
|
作者：
Breadner, Daniel Adam
Welch, Stephen
Jonker, Derek J.
Klimo, Paul
Cripps, M. Christine
Biagi, James Joseph
Lam, Wendy
Whiston, Frances
Stitt, Larry
Vincent, Mark David
机构：
[1] Schulich Sch Med & Dent, London, ON, Canada
[2] London Reg Canc Program, London, ON, Canada
[3] Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[4] Continuum Med Care Ltd, W Vancouver, BC, Canada
[5] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[6] Canc Ctr Southeastern Ontario, Kingston, ON, Canada
[7] Burnaby Hosp, Reg Canc Ctr, Burnaby, BC, Canada
[8] London Hlth Sci Ctr, London, ON, Canada
[9] Univ Western Ontario, London, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.745
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
745
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II trial of capecitabine in relapsed ovarian cancer.
    Vasey, P
    McMahon, L
    Paul, J
    Kaye, S
    ANNALS OF ONCOLOGY, 2000, 11 : 84 - 84
  • [32] Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer
    Jimeno, Antonio
    Gravalos, Cristina
    Escudero, Pilar
    Sevilla, Isabel
    Eugenia Vega-Villegas, M.
    Alonso, Vicente
    Juez, Ignacio
    Garcia-Carbonero, Rocio
    Bovio, Humberto
    Colomer, Ramon
    Cortes-Funes, Hernan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (01): : 52 - 57
  • [33] Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer
    Antonio Jimeno
    Cristina Grávalos
    Pilar Escudero
    Isabel Sevilla
    M. Eugenia Vega-Villegas
    Vicente Alonso
    Ignacio Juez
    Rocío García-Carbonero
    Humberto Bovio
    Ramón Colomer
    Hernán Cortés-Funes
    Clinical and Translational Oncology, 2008, 10 : 52 - 57
  • [34] Phase II study of gemcitabine, capecitabine and cisplatin in patients with advanced pancreatic cancer.
    Chang, HM
    Kim, TW
    Ahn, JH
    Ryu, MH
    Lee, JS
    Kim, WK
    Kang, YK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 368S - 368S
  • [35] A phase II trial of capecitabine plus irinotecan (XELIRI) in a biweekly schedule in patients with untreated metastatic colorectal cancer (MCRC)
    Garcia Alfonso, Pilar
    Perez-Manga, Gumersindo
    Gonzalez, M. C.
    Lopez, P.
    Gonzalez, E.
    Belon, J.
    Molina, M.
    Pachon, V.
    Iglesias, L.
    Munoz, V.
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 120
  • [36] Temozolimide and capecitabine in heavily pre-treated patients with KRASmut metastatic colorectal cancer. A phase II trial
    Qvortrup, C.
    Keldsen, N.
    Andersen, F.
    Jensen, H. A.
    Krogh, M.
    Vestermark, L. W.
    Christensen, G.
    Bjerregaard, J. K.
    Pfeiffer, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S380 - S380
  • [37] Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study
    Price, T. J.
    Townsend, A. R.
    Khattak, A.
    ANNALS OF ONCOLOGY, 2010, 21 (10) : 2121 - 2121
  • [38] Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study
    Rosati, G.
    Cordio, S.
    Bordonaro, R.
    Caputo, G.
    Novello, G.
    Reggiardo, G.
    Manzione, L.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 781 - 786
  • [39] Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients
    Frustaci, Sergio
    Buonadonna, Angela
    Turchet, Elisa
    Corona, Giuseppe
    Tabaro, Gianna
    Miolo, GianMaria
    Torrisi, Elena
    Lo Re, Giovanni
    Tumolo, Salvatore
    Toffoli, Giuseppe
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 510 - 516
  • [40] Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients
    Sergio Frustaci
    Angela Buonadonna
    Elisa Turchet
    Giuseppe Corona
    Gianna Tabaro
    GianMaria Miolo
    Elena Torrisi
    Giovanni Lo Re
    Salvatore Tumolo
    Giuseppe Toffoli
    International Journal of Clinical Oncology, 2013, 18 : 510 - 516
12345